Advertisement

Search Results

Advertisement



Your search for The ASCO Post matches 511 pages

Showing 1 - 50


lung cancer

Suresh S. Ramalingam, MD, on Osimertinib vs Comparator EGFR TKI in EGFR-Mutated NSCLC: The FLAURA Trial

Suresh S. Ramalingam, MD, of Emory University, discusses results from the final overall survival analysis of the phase III FLAURA trial in EGFR-mutated advanced non–small cell lung cancer, which showed that osimertinib provided a survival benefit vs comparator EGFR tyrosine kinase inhibitor therapy ...

lung cancer
immunotherapy

Solange Peters, MD, PhD, on NSCLC: CheckMate 227 Trial of Nivolumab/Ipilimumab vs Chemotherapy

Solange Peters, MD, PhD, of the Oncology Department of CHUV, discusses study findings from the first phase III trial to show PD-1 and CTLA-4 inhibition is effective in non–small cell lung cancer, with improved overall survival vs chemotherapy (Abstract LBA4).

lung cancer

Laura Q.M. Chow, MD, on Metastatic NSCLC: Results of the ASCEND-7 Trial on Ceritinib

Laura Q.M. Chow, MD, of the University of Texas at Austin, Dell Medical School and LIVESTRONG Cancer Institutes, discusses phase II study findings that showed the ALK inhibitor ceritinib achieved durable intracranial response in patients with ALK-positive non–small cell lung cancer that has spread...

lung cancer
immunotherapy

Andreas Rimner, MD, on the PACIFIC Trial: Durvalumab for Stage III NSCLC

Andreas Rimner, MD, of Memorial Sloan Kettering Cancer Center, discusses study findings showing that, for patients with stage III non–small cell lung cancer, durvalumab reduced the rate of and time to disease progression vs placebo and also reduced the number of new distant lesions (Abstract LBA6).

lung cancer

Cristina Merkhofer, MD, MHS, on NSCLC: Survival Impact of Taking Part in a Clinical Trial

Cristina Merkhofer, MD, MHS, of Fred Hutchinson Cancer Research Center, discusses study results showing that for patients with metastatic non–small cell lung cancer at her institution, enrolling in a therapeutic drug clinical trial was associated with a 47% lower risk of death, compared with not...

cost of care
lung cancer

Bernardo H.L. Goulart, MD, on Stage IV NSCLC: High Drug Costs May Affect Survival

Bernardo H. L. Goulart, MD, of Seattle Cancer Care Alliance, discusses his findings that high out-of-pocket costs for oral tyrosine kinase inhibitors may lower survival rates, shorten the duration of therapy, and reduce the number of prescriptions for patients with metastatic EGFR- or ALK-positive...

breast cancer
colorectal cancer
head and neck cancer
lung cancer

FDA Approves Entrectinib for NTRK-Fusion Cancers, ROS1-Positive NSCLC

Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to entrectinib (Rozlytrek) for adult and adolescent patients whose cancers have an NTRK (neurotrophic tyrosine receptor kinase) genetic fusion and for whom there are no effective treatments. Entrectinib was also...

leukemia
lung cancer
sarcoma
immunotherapy

FDA Pipeline: Label Update for Durvalumab in NSCLC; Applications Accepted in Epithelioid Sarcoma, AML

Recently, the U.S. Food and Drug Administration (FDA) approved the inclusion of overall survival from the PACIFIC trial in the U.S. prescribing information for durvalumab and accepted applications for a new drug in the treatment of epithelioid sarcoma and two orphan drugs in the treatment of acute...

lung cancer
issues in oncology

Deep Natural Language Processing of Oncology Radiology Reports

Scientists have demonstrated that an artificial intelligence (AI) tool can perform as well as human reviewers—and much more rapidly—in extracting clinical information regarding changes in tumors from unstructured radiology reports for patients with lung cancer. These findings were...

lung cancer
issues in oncology

Poorer Outcomes for Patients With Lung Cancer Undergoing Radiotherapy During Disaster-Level Hurricanes

Patients who experienced a disaster-level hurricance during radiotherapy for lung cancer had worse overall survival than those who completed treatment in normal circumstances, with longer disaster declarations associated with increasingly worse survival. These findings come from a...

gynecologic cancers
lung cancer
lymphoma
skin cancer
multiple myeloma

FDA Pipeline: Designations and Applications Granted in Lymphoma, Small Cell Lung Cancer, Multiple Myeloma, and More

Recently, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to a phospholipid-drug conjugate in diffuse large B-cell lymphoma; granted Orphan Drug designation to an immunotherapy for small cell lung cancer (SCLC); accepted supplemental biologics license applications (sBLAs) ...

lung cancer
cost of care

Cost-Effectiveness of Single-Marker Genetic Testing vs Multigene Panel Sequencing in Advanced NSCLC

The results of an economic modeling study to estimate the cost-effectiveness of multigene panel sequencing as compared to standard-of-care single-gene tests for patients with advanced non–small cell lung cancer (NSCLC) showed that multigene panel sequencing tests are moderately...

lung cancer

Risk-Prediction Model Aims to Predict Incident Lung Cancer in Patients With a Pulmonary Nodule

A risk-prediction model developed using clinical and radiologic features could stratify individuals presenting with a lung nodule as having a high or low risk for lung cancer, according to a study published by Nemesure et al in Cancer Prevention Research. “While lung nodules are not...

head and neck cancer
lung cancer
issues in oncology

Do Statins Lower the Risk of Cardiovascular Complications in Patients Treated With Radiotherapy to the Chest, Neck, or Head?

Patients with cancer who took cholesterol-lowering statin medication following radiation therapy of the chest, neck, or head had significantly reduced risk of suffering a stroke—and possibly other cardiovascular complications—according to research published by Boulet et al in...

lung cancer

Extended Follow-up From the National Lung Screening Trial Reported

Early detection and treatment through screening with low-dose computed tomography (LDCT) has been investigated as a potential means of reducing lung cancer mortality for more than 2 decades. In 2011, a large U.S. study—the randomized National Lung Screening Trial (NLST)—reported a 20%...

cns cancers
colorectal cancer
gynecologic cancers
kidney cancer
lung cancer

FDA Approves Bevacizumab Biosimilar for Five Cancer Types

On June 28, the U.S. Food and Drug Administration (FDA) approved bevacizumab-bvzr (Zirabev), a biosimilar to bevacizumab (Avastin), for the treatment of five types of cancer: metastatic colorectal cancer; unresectable, locally advanced, recurrent, or metastatic nonsquamous non–small cell ...

lung cancer

FDA Expands Indications for Pembrolizumab to Include Metastatic SCLC With Disease Progression on or After Other Therapies

On June 17, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the anti–programmed cell death protein 1 (PD-1) therapy pembrolizumab (Keytruda) as monotherapy for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease...

lung cancer
issues in oncology

Radiotherapy Increases Adverse Cardiovascular Event Risk for Patients With Lung Cancer

A new retrospective study led by investigators from Brigham and Women’s Hospital and Dana-Farber Cancer Institute examined outcomes for patients after receiving treatment for locally advanced non–small cell lung cancer (NSCLC), finding that the average radiation dose delivered to the...

lung cancer

Justin F. Gainor, MD, on Non–Small Cell Lung Cancer: Clinical Activity and Tolerability of Selective RET Inhibitor

Justin F. Gainor, MD, of Massachusetts General Hospital, discusses updated findings from the ARROW study in which BLU-667, a selective RET inhibitor, demonstrated clinical activity and tolerability in patients with advanced RET fusion–positive non–small cell lung cancer (Abstract 9008).

lung cancer

Luis G. Paz-Ares, MD, PhD, on Small Cell Lung Cancer: Efficacy and Safety of Lurbinectedin

Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 de Octubre, discusses study findings on the second-line use of lurbinectedin in patients with both resistant and sensitive small cell lung cancer (Abstract 8506).

lung cancer
immunotherapy

2019 ASCO: NEOSTAR: Neoadjuvant Nivolumab Plus Ipilimumab in Early-Stage, Resectable NSCLC

Neoadjuvant treatment with nivolumab plus ipilimumab resulted in an overall major pathologic response rate of 33% of treated patients with early-stage, resectable non–small cell lung cancer (NSCLC). With these results, the combination immunotherapy met the prespecified trial...

lung cancer
immunotherapy

Gilberto Lopes, MD, MBA, on the RELAY Trial in Metastatic NSCLC: Erlotinib and Ramucirumab in EGFR Mutant–Positive Disease

Gilberto Lopes, MD, MBA, of the Sylvester Comprehensive Cancer Center at the University of Miami, offers commentary on phase III findings from the RELAY study, which showed that erlotinib plus ramucirumab led to superior progression-free survival in previously untreated patients with EGFR...

lung cancer
immunotherapy

Miriam Knoll, MD, and Richard J. White, DO, on Non–Small Cell Lung Cancer: Predicting Radiotherapy/Immunotherapy Treatment Outcomes

Miriam Knoll, MD, of Hackensack University Medical Center, and Richard J. White, DO, of Allegheny Health Network, discuss improved overall survival among younger female patients with non–small cell lung cancer who have a lower comorbidity score, lower grade, private insurance, and treatment with...

lung cancer
immunotherapy

Suresh S. Ramalingam, MD, on Non–Small Cell Lung Cancer: Pemetrexed, Bevacizumab, or Both as Maintenance Therapy

Suresh S. Ramalingam, MD, of Winship Cancer Institute, Emory University, discusses findings from the ECOG-ACRIN 5508 study, which showed that single-agent bevacizumab or pemetrexed is the optimal maintenance therapy for advanced nonsquamous NSCLC (Abstract 9002).

issues in oncology
lung cancer

Richard L. Schilsky, MD, and R. Donald Harvey, PharmD, BCOP, on Advanced Non–Small Cell Lung Cancer: Expanding the Criteria for Clinical Trial Eligibility

Richard L. Schilsky, MD, of ASCO, and R. Donald Harvey, PharmD, BCOP, of Winship Cancer Institute of Emory University, discuss their study findings that expanding the clinical trial eligibility criteria for patients with advanced NSCLC would enable nearly twice as many people to be considered for...

lung cancer
issues in oncology

2019 ASCO: Expansion of Clinical Trial Inclusion Criteria in Patients With Advanced NSCLC

A study that examined 10,500 health records of patients with advanced non–small cell lung cancer from ASCO’s CancerLinQ database found that the use of expanded clinical trial inclusion criteria—as proposed by ASCO and Friends of Cancer Research in 2017—would nearly double...

lung cancer
immunotherapy

David J. Kwiatkowski, MD, PhD, on Non–Small Cell Lung Cancer: Neoadjuvant Immunotherapy for Resectable Disease

David J. Kwiatkowski, MD, PhD, of Brigham and Women’s Hospital and Dana-Farber Cancer Institute, discusses an interim analysis and biomarker data from a multicenter study showing that 19% of patients with NSCLC had a major pathologic response to preoperative treatment with atezolizumab (Abstract...

lung cancer

Hirotsugu Kenmotsu, MD, on Nonsquamous Non–Small Cell Lung Cancer: Pemetrexed Plus Cisplatin vs Vinorelbine Plus Cisplatin

Hirotsugu Kenmotsu, MD, of Shizuoka Cancer Center, discusses the phase III JIPANG trial findings, which showed that pemetrexed plus cisplatin was not superior to vinorelbine plus cisplatin in terms of recurrence-free survival for patients with completely resected nonsquamous non–small cell lung...

lung cancer

Taofeek Kunle Owonikoko, MD, PhD, on Small Cell Lung Cancer: Tremelimumab and Durvalumab With or Without Radiation

Taofeek Kunle Owonikoko, MD, PhD, of Emory University, discusses the findings of his phase II study, which assessed the efficacy of combined immune checkpoint inhibitors with or without radiation in relapsed small cell lung cancer (Abstract 8515).

lung cancer
immunotherapy

Edward B. Garon, MD, on Advanced Non–Small Cell Lung Cancer: KEYNOTE-001 Trial on Pembrolizumab

Edward B. Garon, MD, of the David Geffen School of Medicine at the University of California, Los Angeles, discusses long-term survival data on patients with advanced non–small cell lung cancer treated with pembrolizumab and those with PD-L1 expressed in at least half of their tumor cells (Abstract...

lung cancer
immunotherapy

2019 ASCO: KEYNOTE-001: 5-Year Survival Data for Patients With Advanced NSCLC Treated With Pembrolizumab

Five-year data from the phase Ib KEYNOTE-001 trial showed that treatment with pembrolizumab was safe and effective and substantially increased overall survival in patients with advanced non–small cell lung cancer (NSCLC). Specifically, 23.2% of people who had not previously been treated with...

lung cancer
immunotherapy

Addition of Bevacizumab to Carboplatin/Pemetrexed in Nonsquamous NSCLC

New research published by Bagley et al in JNCCN—Journal of the National Comprehensive Cancer Network used a large real-world data set to demonstrate a modest but consistent survival benefit associated with adding bevacizumab to carboplatin/pemetrexed in advanced nonsquamous non–small...

lung cancer

FDA Approves the NovoTTF-100L System in Combination With Chemotherapy for Malignant Pleural Mesothelioma

On May 23, the U.S. Food and Drug Administration (FDA) approved the NovoTTF-100L System in combination with pemetrexed plus platinum-based chemotherapy for the first-line treatment of unresectable locally advanced or metastatic malignant pleural mesothelioma. NovoTTF-100L is a noninvasive,...

breast cancer
lung cancer
issues in oncology

ACCURE Trial: Improving Racial Disparities in Treatment for Patients With Early-Stage Lung and Breast Cancers

Results from a study published by Cykert et al in The Journal of the National Medical Association show that a pragmatic system-based intervention within cancer treatment centers can nearly eliminate existing disparities in treatment and outcomes for black patients with early-stage...

breast cancer
lung cancer
skin cancer

Lifetime Risk of Brain Metastases in Elderly Survivors of Breast, Lung, and Skin Cancers

Elderly survivors of breast cancer, lung cancer, and melanoma face risk of brain metastasis later in life, and may require extra surveillance in the years following initial cancer treatment, according to results of a study published by Ascha et al in Cancer Epidemiology, Biomarkers, &...

lung cancer

ESTRO 38: Radical Hemithoracic Therapy in Patients With Mesothelioma

Patients with mesothelioma are twice as likely to survive for 2 years or longer if they are treated with a high dose of radiation to the affected side of the trunk, according to research presented by Minatel et al at ESTRO 38, the annual congress of the European Society for Radiotherapy...

lung cancer
immunotherapy

FDA Expands Pembrolizumab Indication for NSCLC in First-Line Setting

Today, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for the first-line treatment of patients with stage III non–small cell lung cancer (NSCLC) who are not candidates for surgical resection or definitive chemoradiation, or those with metastatic NSCLC....

lung cancer
immunotherapy

ELCC 2019: Does Maintenance Immunotherapy Improve Survival in Patients With Advanced SCLC?

Maintenance immunotherapy did not improve survival in patients with extensive-stage small cell lung cancer (SCLC), according to late-breaking results from the CheckMate 451 study presented today by Owonikoko et al at the European Lung Cancer Congress 2019 (Abstract LBA1_PR). Around 60% to 70% of...

lung cancer
issues in oncology
immunotherapy

ELCC 2019: Immunotherapy in Elderly Patients With Advanced NSCLC

Two studies reported at the European Lung Cancer Congress (ELCC) 2019 provided new insights on the efficacy and safety of immunotherapy in elderly patients with advanced non–­small cell lung cancer (NSCLC). Although around half of all people newly diagnosed with NSCLC are elderly (Pallis ...

lung cancer

Lung Cancer Organizations Join Forces to Launch GO2 Foundation for Lung Cancer

Two nonprofit organizations serving the lung cancer community—the Bonnie J. Addario Lung Cancer Foundation (ALCF) and Lung Cancer Alliance (LCA)—have announced they are joining forces as the GO2 Foundation for Lung Cancer. With more than 3 decades of combined expertise, a...

lung cancer

Ultradeep Next-Generation Sequencing in Patients With Lung Cancer

A new method of determining the sequence of molecules in DNA can be used to detect small fragments of cancerous genetic material in blood samples from patients with lung cancer with a high degree of accuracy, according research published by Li et al in Annals of Oncology. Liquid Biopsies and...

immunotherapy
lung cancer

Matthew A. Gubens, MD, on Non–Small Cell Lung Cancer: New Immunotherapy Strategies in the NCCN Guidelines

Matthew A. Gubens, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discusses recent updates to the NCCN Guidelines in non–small cell lung cancer, including the use of pembrolizumab as a single agent or in combination based on PD-L1 status, treatment selection in squamous and...

lung cancer
immunotherapy

Jyoti D. Patel, MD, on Stage III Non–Small Cell Lung Cancer: A Look at New Systemic Treatments

Jyoti D. Patel, MD, of the University of Chicago, discusses immunotherapy for locally advanced NSCLC, selecting patients for these treatments, and the potential toxicities of combination therapies.

lung cancer

Susan Y. Wu, MD, on Non–Small Cell Lung Cancer: Using an Online Tool in Treatment

Susan Y. Wu, MD, of the University of California, San Francisco, discusses how patient exposure to treatment guidelines improved smoking cessation counseling and the use of molecular testing, and decreased the use of adjuvant chemotherapy in patients with early-stage disease (Abstract 5).

lung cancer
symptom management

Mark K. Ferguson, MD, on Mitigating Frailty and Sarcopenia to Improve Treatment Outcomes

Mark K. Ferguson, MD, of the University of Chicago Hospital, discusses frailty and loss of muscle tissue, which are common among patients with lung cancer. These conditions are linked with decreased survival as well as increased surgical complications, chemotherapy toxicity, and cost of care.

lung cancer

Jing Zeng, MD, on Non–Small Cell Lung Cancer: Therapeutic Implications of Proper Disease Staging

Jing Zeng, MD, of the University of Washington, discusses upstaging disease from stage III to stage IV, which can occur with repeat PET and/or CT scans for patients with locally advanced NSCLC, and the need for clinicians to stage disease properly to ensure appropriate treatment.

lung cancer
immunotherapy

Ruqin Chen, MB, on Lung Cancer Treated With Immune Checkpoint Inhibitors: Survival Outcomes and Clinical and Molecular Features

Ruqin Chen, MB, of the Mayo Clinic Florida, discusses early study findings that show molecular profiling with NF1, CD79a, and AKT3 could potentially improve prediction of progression-free survival in patients with lung cancer who are receiving immunotherapy.

lung cancer
issues in oncology

Kyle F. Concannon, MD, on Lung Cancer in Homeless Patients: Outcomes and Quality Measures

Kyle F. Concannon, MD, of the University of Washington/Seattle Cancer Care Alliance, discusses study results on the delays in biopsy after radiographic findings among homeless vs housed patients with lung cancer, and the higher rates of missed appointments following diagnosis (Abstract 125).

lung cancer

J. Fletcher Drogos, MD, on Multiple Courses of Stereotactic Body Radiation Therapy: Outcomes in Patients With Lung Cancer

J. Fletcher Drogos, MD, of Rush University, discusses study findings on overall survival and toxicity among patients who undergo multiple radiation treatments for lung cancer.

lung cancer
issues in oncology

Shraddha M. Dalwadi, MD, MBA, on Non–Small Cell Lung Cancer: What Contributes to Disparities in Treating Stage I Disease

Shraddha M. Dalwadi, MD, MBA, of Baylor College of Medicine, discusses the nearly 12% of potentially curable patients with stage I NSCLC who do not receive treatment, the various socioeconomic reasons why, and how some patients may benefit from minimally invasive therapies (Abstract 127).

Advertisement

Advertisement



Advertisement